CD44 and cancer: Alternative splicing is often deregulated in cancer, probably as a consequence of quantitative alterations in the levels of expression of splicing regulators [21]; however, many examples of cancer-specific gene isoforms (CD44, BRCA1, survivin etc), whose expression seem to correlate with the disease, have been described in literature [22].